Novartis AG is a global healthcare company that specializes in developing and manufacturing innovative pharmaceuticals and medical products. The company focuses on research-driven solutions in various therapeutic areas, including oncology, cardiology, immunology, and neuroscience, among others. Novartis is committed to improving patient health by providing high-quality medications and treatments, and it invests significantly in research and development to discover and deliver new therapies. In addition to its pharmaceutical division, Novartis also offers generics and biosimilars through its Sandoz division, making healthcare more accessible to patients worldwide. Read More
The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania.
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.
Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.
The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.
NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector.
